Comparing two doses of MyCondro for knee joint mobility

A Randomized, Double-blind Study Evaluating the Effectiveness of Two Different Doses of MyCondroTM on Physical Mobility and Joint Health Using Participant-Reported Outcomes in Individuals With Self-Reported Mobility Issues Associated With Knee Osteoarthritis

This will see if taking 300 mg or 600 mg of MyCondro helps adults 45 and older with knee osteoarthritis reduce pain and improve mobility.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 240 (estimated)
• Ages: 45 Years and up
• Sex: All
• Sponsor: Lesaffre International (Industry-sponsored)
• Locations: 1 site (Los Angeles, California)
• Trial ID: NCT07493239 on ClinicalTrials.gov

What this trial studies

This decentralized, double-blind, randomized consumer-driven study assigns adults 45 and older with self-reported knee osteoarthritis to either 300 mg or 600 mg of MyCondro for a 12-week product use period. The primary outcome is change in total WOMAC score from baseline to the end of treatment, while secondary outcomes include pain, stiffness, knee function, patient-reported global improvement, CRP inflammatory markers, and wearable-tracked physical activity. All procedures are conducted remotely through a smartphone app with study product shipped to participants and both participants and investigators blinded to dose assignment. The design is intended to generate real-world tolerability and efficacy data to guide future formulation and trial planning.

Who should consider this trial

Good fit: Ideal candidates are adults aged 45 or older with BMI 18–35 kg/m², self-reported knee osteoarthritis with mobility impairment for at least six months, able to read English, use a smartphone app, and receive shipments within the United States.

Not a fit: People with more severe or surgically managed knee osteoarthritis, those outside the BMI or age ranges, those unable to avoid chondroitin-containing foods or supplements, or those without smartphone access are less likely to benefit from or be eligible for this study.

Why it matters

Potential benefit: If successful, the product could offer a non-animal chondroitin option that modestly improves pain, stiffness, and mobility for people with knee osteoarthritis.

How similar studies have performed: Prior trials of animal-derived chondroitin have shown mixed but occasionally modest improvements in pain and function, while non-animal chondroitin formulations like this one are less well studied.

Eligibility criteria

Inclusion Criteria:

* Individuals age 45 years and older.
* BMI range between 18-35 kg/m².
* Self-reported mobility issues, including mobility impairment and joint discomfort associated with a known diagnosis of Knee Osteoarthritis. This impairment and discomfort must have persisted for at least 6 months prior to randomization and have been actively experienced within the last 3 months.
* Willingness to avoid high Chondroitin Sulfate-containing foods (i.e., animal cartilages, bones, or derivatives such as gelatin) for the duration of the study period.
* Willingness to refrain from supplements containing Chondroitin Sulfate for the duration of the study period.
* Able to read and understand English.
* Able to read, understand, and provide informed consent.
* Able to use a personal smartphone device and download the Chloe by People Science app.
* Able to receive shipments of the product at an address within the United States.
* Able to complete study assessments over the course of up to 16 weeks.

Exclusion Criteria:

Any potential participants will be excluded if they meet any of the following criteria:

* Technology Limitation: Do not have a personal smartphone, lack internet access, or are unwilling to download the Chloe app.
* Concomitant Therapies

  1. Use of a Chondroitin Sulfate supplement in the 3 months prior to randomization.
  2. Current use of other joint health supplements (e.g., glucosamine, hyaluronic acid, collagen peptides) for at least 4 weeks prior to randomization.
  3. Use of any intra-articular or intravenous steroid injections in the last 3 months.
  4. Receiving any investigational therapies or treatments within 30 days prior to randomization.

Other Illnesses or Conditions

1. Self-reported inflammatory arthropathies, such as Rheumatoid Arthritis, Gout, and Infectious Arthritis.
2. Significant systemic lung, liver, heart, or kidney disease (excluding hypertension).
3. Prior history of knee surgery within 3 months preceding the study period, or planned knee surgery (including arthroscopy) during the study period.
4. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder.
5. Currently pregnant, planning to become pregnant in the next 20 weeks, or breastfeeding.
6. Presence of a knee prosthesis.
7. Any significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes.

Allergies and Intolerances

1. Known hypersensitivity or previous allergic reaction to: Chondroitin sulfate, Maltodextrin, Mannitol, Magnesium Stearate, Silicon dioxide, Microcrystalline cellulose, or Talc.
2. Known sensitivity or intolerance to wheat or gluten.

General Compliance

1- Unlikely for any reason to be able to comply with the trial, or considered unsuited for participation in the study by the Principal Investigator.

Where this trial is running

Los Angeles, California

• People Science — Los Angeles, California, United States (Recruiting)

Study contacts

• Principal investigator: Noah Craft, MD, PhD — People Science
• Study coordinator: Victoria Oyedokun, PhD

Conditions Joint Health; MyCondro, Gnosis, PS24; Joint function; Joint mobility; non-animal chondroitin sulfate